Balancing benefits and harms of treatments for acute bipolar depression  by Ketter, Terence A. et al.
 Journal of Affective Disorders 169 S1 (2014) S24–S33 
a r t i c l e  i n f o
Article history:
Received 15 May 2014
Received in revised form 8 August 2014
Accepted 3 September 2014
Keywords:
Antidepressants
Antipsychotics
Olanzapine plus fluoxetine
Quetiapine
Lurasidone
Lamotrigine
Antidepressants
Armodafinil
Bipolar depression
Bipolar disorder
Mood stabilizers
Number needed to harm
Number needed to treat
a b s t r a c t
Background: Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments.
Methods: Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-
analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm 
(NNH) for selected side effects for older and newer acute bipolar depression treatments.
Results: The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination 
(OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), 
but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). 
Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) 
tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of 
inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the 
newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 
as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], 
NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy 
in bipolar depression has not been consistently demonstrated in randomized controlled trials.
Limitations: NNT and NNH are categorical metrics; only selected NNHs were assessed; limited 
generalizability of efficacy (versus effectiveness) studies.
Conclusions: For acute bipolar depression, older approved treatments may have utility in high-urgency 
situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly 
approved lurasidone may ultimately prove useful in diverse situations. New drug development needs 
to focus on not only efficacy but also on tolerability.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
Bipolar disorder (BD) is a common, recurrent, frequently 
debilitating and, in many instances, tragically fatal illness, 
characterized by oscillations in mood, energy, and ability to 
function (American Psychiatric Association, 2013). BD, in its 
broadest sense, may affect as much as 4% of the population 
(Merikangas et al., 2007) and ranks second among mental illnesses 
causing disability in working-age adults (Murray and Lopez, 
1997). Depressive compared with manic states are more pervasive 
(Judd et al., 2003; Judd et al., 2002) and, thus, crucially contribute 
to functional impairment (Altshuler et al., 2002; Judd et al., 
2005). Although approximately 20% of BD patients may attempt 
suicide (Rihmer and Kiss, 2002), most often during depression 
(Pompili et al., 2013; Valtonen et al., 2008), many succumb to 
premature cardiovascular, cerebrovascular, gastrointestinal, or 
other medical causes of mortality (Osby et al., 2001). There are 
fewer evidence-based treatments for bipolar depression than for 
mania, and the older treatments approved by the US Food and 
Drug Administration (FDA) for acute bipolar depression involve 
risks of substantial side effects, such as sedation/somnolence that 
can impair function and weight gain/metabolic complications 
that can increase the risk of mortality (Sanford and Keating, 2012; 
Silva et al., 2013). This suggests that new, well-tolerated, effective 
treatment options are needed. In this article, we describe an 
approach for evaluating the potential benefits and risks of older, 
newer approved, unapproved, and emerging treatments for acute 
bipolar depression.
2. Methods
2.1 Data sources
The published scientific literature and proceedings of 
recent major scientific meetings (e.g., the American Psychiatric 
Association, the American College of Neuropsychopharmacology) 
were searched for randomized, double-blind, placebo-controlled 
trials of the efficacy of pharmacotherapies for acute bipolar 
depression. For the published scientific literature, the PubMed 
database was searched using the search terms “bipolar,” “bipolar 
disorder,” “bipolar I disorder,” “bipolar II disorder,” “bipolar 
depression,” “randomized,” “controlled,” “treatment,” “efficacy,” 
“effectiveness,” “lithium,” “carbamazepine,” “divalproex,” “val-
proate,” “lamotrigine,” “olanzapine,” “risperidone,” “quetiapine,” 
“ziprasidone,” “aripiprazole,” “asenapine,” “lurasidone,” “anti-
depressants,” and “armodafinil”.
2.2 Study selection
Large (N>100), randomized, double-blind, placebo-controlled 
trials of the efficacy of pharmacotherapies for acute bipolar 
depressive episodes in patients with well-defined bipolar I 
disorder or bipolar II disorder were selected. For antidepressants, 
a recent meta-analysis was selected. Studies whose primary 
emphasis was not the treatment of BD and studies not reporting 
response/remission rates and side effect rates were excluded.
2.3 Outcome measures
The efficacy variable was number needed to treat (NNT) 
for acute response (percentage of subjects with at least 50% 
improvement in mood rating) compared with placebo for 
acute bipolar depressive episodes. NNT, the expected number 
of subjects who would need to be treated to yield 1 additional 
good outcome, compared with a control intervention (Citrome, 
2008; Citrome, 2009b; Laupacis et al., 1988), was calculated for 
response in acute bipolar depression (i.e., at least a 50% decrease 
in depressive symptoms), by assessing the reciprocal of the 
absolute risk reduction (difference in the response rates for a 
treatment and a control intervention) (Citrome, 2008; Laupacis et 
al., 1988). For example, if a medication and placebo had response 
rates of 50% and 25%, respectively, the NNT for response was 
100% / (50%–25%) = 100% / 25% = 4. That is, 4 patients would need 
to be treated to expect to obtain 1 more response compared with 
placebo. We followed the convention of rounding up NNT to the 
next higher integer (Sackett and Straus, 1998), although some 
have advocated that NNTs from 1 to 100 ought to be reported to at 
least 1 decimal place (Stang et al., 2010). Lower NNTs represented 
better outcomes, with single digits (preferably low single digits) 
generally representing adequate outcomes in BD.
Harms (adverse effects) were quantified using the number 
needed to harm (NNH), the number of patients who would have 
to be treated before 1 additional patient would be expected 
to experience an adverse effect, compared with a control 
intervention (Ketter et al., 2011). NNH for adverse effects were 
calculated by assessing the reciprocal of the absolute risk increase 
(difference in the adverse effect rates for a treatment and a control 
intervention). For example, if a medication and placebo had 
sedation/somnolence rates of 40% and 20%, respectively, the NNH 
for sedation/somnolence was 100% / (40% – 20%) = 100% / 20% = 5. 
That is, 5 patients would need to be treated to expect to encounter 
1 more with sedation/somnolence compared with placebo. We 
followed the convention of rounding up NNH to the next higher 
integer.
Ninety-five percent confidence intervals (95% CIs) for NNT and 
NNH were also calculated to facilitate comparisons of likelihoods 
of benefits (NNTs) versus harms (NNHs) (Citrome, 2009a). In 
instances where there was no significant difference between 
active treatment and placebo with respect to efficacy (NNT) and/
or tolerability (NNH), the (infinite/discontinuous) 95% CI was 
reported as not significant (NS). In other instances (with finite, 
continuous 95% CIs for both NNT and NNH), if the upper limit of 
the 95% CI for NNT was less than the lower limit of the 95% CI 
for NNH, the active treatment was deemed more likely to yield 
benefit than harm; if the 95% CIs for NNT and NNH overlapped, the 
active treatment was deemed comparably likely to yield benefit 
and harm; and if the upper limit of the 95% CI for NNH was less 
than the lower limit of the 95% CI for NNT, the active treatment 
was deemed to be more likely to yield harm than benefit.
For each bipolar depression medication we determined the 
clinically relevant adverse effect resulting in the greatest increase 
in harm over placebo (i.e., the adverse effect yielding the lowest 
NNH, based on available published data). Thus, we reported NNH 
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for sedation/somnolence for quetiapine and lamotrigine, at least 
7% weight gain for olanzapine and olanzapine plus fluoxetine, 
treatment-emergent affective switch (TEAS) for antidepressants as 
a class and paroxetine specifically, akathisia/nausea for lurasidone 
monotherapy/adjunctive therapy, and anxiety for armodafinil 
adjunctive therapy.
2.4 Data extraction
Two of the authors (S.M. and T.K.) extracted data from 
individual studies. The following data were recorded: authors and 
years of publication, number of subjects using active treatments 
and control interventions, doses, NNT, NNH, and related 95% CIs.
2.5 Data analysis
Analyses of NNT for response and NNH for side effects, and 
related 95% CIs were conducted using the retrieved reports. When 
more than one study was available for a particular agent, overall 
NNT, NNH, and related 95% CIs were obtained by sample-size 
weighted pooling of individual study data.
3. Currently available treatments
As of late 2014, the FDA had approved pharmacotherapy 
indications for 13 treatments for the management of BD 
(Table 1) (Ketter and Wang, 2010). These indications were 
based on treatment phases. Most of the approved indications 
were for acute mania, including 10 monotherapy approvals 
and 5 adjunctive therapies (added to lithium or valproate). In 
contrast, for the indication of acute bipolar depression, only 
2 monotherapies (lurasidone, quetiapine), 1 combination 
therapy (olanzapine plus fluoxetine), and 1 adjunctive therapy 
(lurasidone, added to lithium or valproate) had been approved. 
Only 1 agent (quetiapine) had FDA indications for both acute 
mania and acute bipolar depression.
Although the mood stabilizers (MSs) lithium, valproate, 
lamotrigine, and carbamazepine are opined by some to be the 
foundational pharmacotherapies for BD, second-generation 
antipsychotics (SGAs) have been increasingly used (Ketter et al., 
2011). In addition, antidepressants, other anticonvulsants, and 
novel therapeutic agents are commonly combined with MSs and 
SGAs in clinical settings (Ketter et al., 2011).
Evidence-based treatment of BD generally begins with 
considering agents approved by the FDA, because such inter-
ventions are considered the most well-established management 
options, having demonstrated efficacy and safety/tolerability 
in adequately sized, multicenter, randomized, double-blind, 
placebo-controlled trials (Table 1). However, clinical needs 
commonly exceed the management options supported by FDA 
indications. In such instances, the next-best treatments are those 
supported by at least 1 adequately sized, randomized, double-
blind, placebo-controlled trial. For bipolar depression, the need for 
treatments with adequate tolerability has been so significant that 
interventions with adequate tolerability but inadequate evidence 
of efficacy, such as lamotrigine and adjunctive antidepressants, 
have been commonly used in the absence of options with both 
adequate efficacy and tolerability.
4. Assessment of potential benefits versus harms
The potential benefits (therapeutic effects) of treatments for 
BD must be considered in the context of potential harms (adverse 
effects). Although the existence of potential benefits and the 
possibility of being worthwhile, in spite of risks of potential harms, 
can be imputed via the existence of FDA indications, clinicians and 
patients commonly desire more detailed assessments of benefit 
versus harm.
In recent years, studies have increasingly quantified potential 
benefits and harms by analyzing NNT and NNH, respectively, 
which were described in detail earlier, in section 2.3. Most FDA-
approved treatments for BD have single-digit NNTs (Ketter et al., 
2011). Alternative treatments worth considering may have NNTs 
as high as the low teens in the setting of good tolerability and few 
well-tolerated agents with lower NNTs.
All of the approved treatments for BD have at least 1 boxed 
warning regarding the risk of serious adverse effects (Ketter et 
al., 2011). Although such boxed warnings are clearly important, 
they do not generally represent the most common adverse effects 
that cause treatment discontinuation (e.g., sedation/somnolence, 
weight gain, and akathisia) (Ketter et al., 2011). Higher NNHs 
represent better outcomes, with double digits generally 
representing adequate outcomes, depending on the severity of 
the harm (Ketter et al., 2011). Because treatments should be more 
likely to help than to harm, we strive for interventions with lower 
NNTs than NNHs, commonly with a goal of having no more than 
a single-digit NNT (i.e., at least 10% more efficacy than placebo) 
and at least a double-digit NNH (i.e., no more than 10% excess 
risk of adverse effects over placebo) (Ketter et al., 2011). Striving 
for an NNH higher than twice the NNT can further increase the 
likelihood of good versus bad outcomes, with help being more 
than twice as likely as harm compared with placebo.
In this article, for each acute bipolar depression medication we 
report NNH for the clinically relevant adverse effect resulting in 
Table 1
FDA-approved treatments for bipolar disorder.*
 Acute Mania Acute Bipolar Depression Bipolar Maintenance
Year† Drug Year† Drug Year† Drug
1970 Lithium (P) 2003 Olanzapine + fluoxetine combination 1974 Lithium (P)
1973 Chlorpromazine 2006 Quetiapine, XR (2008)  2003 Lamotrigine
1994 Divalproex, ER (2005) 2013 Lurasidone‡  2004 Olanzapine
2000 Olanzapine (P)‡   2005 Aripiprazole (P)‡
2003 Risperidone (P)‡   2008 Quetiapine, XR (adjunct)
2004 Quetiapine, XR (2008) (P)‡   2009 Risperidone LAI‡
2004 Ziprasidone   2009 Ziprasidone (adjunct)
2004 Aripiprazole (P)‡    
2004 Carbamazepine ERC    
2009 Asenapine‡    
* Adapted with permission from the Handbook of Diagnosis and Treatment of Bipolar Disorders, (Copyright © 2010). American Psychiatric Association. (Wang and 
Ketter, 2010) All rights reserved.
† Year indicates when FDA adult approval was granted for these indications.
‡ Adjunctive and monotherapy.
ER, ERC, XR = extended-release oral formulations, FDA = US Food and Drug Administration, LAI = long-acting injectable formulation, P = pediatric and adult.
 T.A. Ketter et al. / Journal of Affective Disorders 169 S1 (2014) S24–S33 S27
the greatest increase in harm over placebo (i.e,. the adverse effect 
yielding the lowest NNH, based on available published data). 
For example, although many clinicians are concerned about the 
potential for serious rash as an adverse effect of lamotrigine, the 
prevalence of serious rash in lamotrigine-treated patients is low 
(1 in 1000 to 1 in 2000) (Calabrese et al., 2002), and placebo-
controlled studies of lamotrigine for acute bipolar depression 
yielded an NNH for benign rash of 44 (Calabrese et al., 2008; 
Ketter et al., 2011). However, the NNH for sedation/somnolence in 
such studies was 37 (Calabrese et al., 2008). We therefore report 
NNH for sedation/somnolence as the most clinically relevant 
harm to consider when evaluating potential risks and benefits of 
lamotrigine treatment for acute bipolar depression. Alternative 
measures of potential harms that we do not report in this article 
include NNH for all-cause discontinuation and NNH for adverse-
effect–related discontinuation of drug compared with placebo. 
Although such metrics may yield more integrative information 
about medication tolerability than NNHs for individual adverse 
effects, discontinuation rates in clinical trials may be confounded 
by variable degrees of patient motivation to complete the study. 
As a result, NNHs for all-cause and adverse-effect–related 
discontinuation may underestimate clinically relevant harms 
associated with a drug compared with placebo that are likely 
to be encountered in routine practice. Indeed, such NNHs are 
commonly higher than those for spontaneously reported specific 
adverse effects, and occasionally are even negative.
Risk-management strategies vary markedly among clinicians 
as well as among patients, so it is crucial to personalize benefit-
versus-harm assessments. It is commonly opined that treatments 
that are more potent with respect to therapeutic effects (i.e., have 
lower NNTs) also tend to be more potent with respect to adverse 
effects (i.e., have lower NNHs), whereas treatments that are more 
tolerable (i.e., have lower risk of adverse effects and higher NNHs) 
also tend to be less potent with respect to therapeutic effects (i.e., 
have higher NNTs). However, systematic data supporting such 
opinions are limited. Some investigators believe that the rank 
orders for potency for both therapeutic and adverse effects of 
interventions may be broadly similar within drug classes, and by 
class from highest to lowest may be: (1) SGAs, (2) MSs (other than 
lamotrigine), and (3) lamotrigine and antidepressants (Figure 1). 
Again, however, systematic data supporting this notion are limited.
In the clinical management of more urgent situations 
(e.g., treatment of severe acute symptoms), a compelling and 
immediate need for efficacy (i.e., lower NNT) may mitigate the 
increased risk of adverse effects (i.e., lower NNH) of more potent 
treatments, such as SGAs (Ketter et al., 2011). During less urgent 
situations (e.g., treatment of mild subacute symptoms or during 
maintenance treatment), a greater need for tolerability (i.e., 
higher NNH) may mitigate the increased risk of inefficacy (i.e., 
higher NNT) of more tolerable treatments (Ketter et al., 2011). In 
fact, it is common to encounter the clinical approach of starting, 
in less urgent situations, with better-tolerated treatments (such 
as lamotrigine or antidepressants, if appropriate) in spite of less 
robust therapeutic effects, before proceeding to treatments with 
greater potential therapeutic effects (such as MSs and SGAs, if 
necessary) but also potentially greater risks of adverse effects.
Fig 1. Schematic for adverse effects of psychotropic medications. The rank orders for potency may be perceived to be broadly similar for the therapeutic and adverse effects 
of psychotropic medications, ranging from highest to lowest as follows: (1) second-generation antipsychotics (SGAs), (2) mood stabilizers (MSs; other than lamotrigine), 
and (3) lamotrigine/antidepressants, although systematic data supporting this notion are limited. However, newer compared with older treatment options commonly 
represent tolerability enhancements. Hence, the newer SGAs ziprasidone, aripiprazole, asenapine, and lurasidone may entail less risk of adverse effects than the older 
SGAs clozapine, olanzapine, risperidone, and quetiapine. Similarly, the newer MS lamotrigine may entail less risk of adverse effects than the older MSs lithium, valproate, 
and carbamazepine. The antidepressants fluoxetine, sertraline, paroxetine, escitalopram, citalopram, desmethyl-venlafaxine, venlafaxine, duloxetine, bupropion, and 
mirtazapine may entail fewer adverse effect risks than the MSs or SGAs. Clinicians commonly adopt a “tolerability-first” approach, starting (if appropriate) with agents 
with fewer side effects at the potential expense of poorer efficacy before moving on (if necessary) to agents with more robust efficacy at the potential expense of poorer 
tolerability. NNH = number needed to harm.
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Controlled trials (at least for acute mania) support the notion 
that combination therapy has more potency than monotherapy 
for both therapeutic and adverse effects (Scherk et al., 2007; Smith 
et al., 2007). Thus, a common approach in less urgent situations is 
to start with monotherapy (if appropriate) before proceeding to 
combination therapy (if necessary).
5. Treatments for bipolar depression
In 2003, the first treatment for acute bipolar depression – 
olanzapine plus fluoxetine combination – received FDA approval 
for patients with bipolar I disorder (Tohen et al., 2003). In 2006, 
quetiapine monotherapy received FDA approval for acute bipolar 
depression, not only in patients with bipolar I disorder, but 
also in patients with bipolar II disorder (Calabrese et al., 2005; 
Thase et al., 2006). Unfortunately, subsequent adequately sized, 
multicenter, randomized, double-blind, placebo-controlled 
trials of aripiprazole (as monotherapy [Thase et al., 2008]) and 
ziprasidone (as monotherapy [Lombardo et al., 2012] and as 
an adjunct to lithium, valproate, or lamotrigine [Sachs et al., 
2011]) for acute bipolar depression were negative. However, as 
described in detail below, in 2013, the SGA lurasidone received 
FDA approval for acute bipolar depression in patients with 
bipolar I disorder, both as monotherapy and as an adjunct to 
lithium or valproate.
For the two older FDA-approved treatments for acute bipolar 
depression, double-blind, placebo-controlled studies yielded 
similar single-digit (i.e., <10) NNTs for response compared 
with placebo (4 [95% CI 3–8] for the olanzapine plus fluoxetine 
combination and 6 [5–9] for quetiapine monotherapy) (Figure 2) 
(Calabrese et al., 2005; Thase et al., 2006; Tohen et al., 2003; Wang 
and Ketter, 2010). However, these treatments also had single-digit 
NNHs (6 [4–10] for at least 7% weight gain with the olanzapine 
plus fluoxetine combination, and 5 [4–5] for sedation/somnolence 
with quetiapine). Thus, although these two older FDA-approved 
treatments had adequate efficacy, their utility was substantially 
limited by being comparably likely to yield benefits (response) 
and harms (side effects) compared with placebo.
For olanzapine monotherapy, 2 double-blind, placebo-con-
trolled studies yielded similar double-digit NNTs for response 
compared with placebo (12 [7–63] in the first study and 11 
[6–1130] in the second study) (Figure 3) (Tohen et al., 2012; Tohen 
et al., 2003; Wang and Ketter, 2010). Moreover, these treatments 
had single-digit NNHs for at least 7% weight gain (6 [5–7] in 
the first study and 5 [4–6] in the second study). Thus, although 
olanzapine monotherapy had evidence of limited efficacy, its 
utility was even more substantially limited by almost (the 95% CIs 
of the single-digit NNHs barely overlapped those of the double-
digit NNTs) being more likely to yield harm (7% weight gain) than 
benefit (response) compared with placebo.
Given that only 3 treatments for acute bipolar depression 
are FDA approved, and the 2 older such treatments are similarly 
likely to yield side effects and response, clinicians have commonly 
considered the use of other treatment options with better 
tolerability, even though these other treatments lack FDA approval 
for acute bipolar depression.
Lamotrigine is FDA-approved for bipolar I maintenance 
treatment, with a particular ability to delay depressive as opposed 
to manic episodes. Aside from serious rash, which may occur 
in as many as 1 in 1000 patients with BD (GlaxoSmithKline, 
2011), lamotrigine has a tolerability profile similar to that of 
antidepressants and superior to that of SGAs and other MSs, such 
as lithium, divalproex, or carbamazepine (Figure 1). In double-
blind, placebo-controlled studies of acute bipolar depression, 
lamotrigine had a favorable double-digit NNH for sedation/
somnolence of 37 (95% CI was NS); however, this was in the 
context of an unfavorable double-digit NNT for response of 12 
(8–41) (Figure 4, left) (Calabrese et al., 2008; Geddes et al., 2009; 
Wang and Ketter, 2010). Thus, although for lamotrigine NNH was 
more than three times the NNT, the favorable benefit/harm ratio 
was offset by inadequate efficacy (as indicated by a double-digit 
NNT).
Fig 2. Benefits and harms of older approved bipolar depression treatments: olanzapine-fluoxetine combination (OFC) and quetiapine. Number needed to treat (response) 
and number needed to harm (adverse effect rates). Older approved treatments were similarly likely to yield benefit and harm compared with placebo. aData from Tohen 
et al, 2003, Arch. Gen. Psychiatry, 60 (11), 1079–1088. Number of patients, OFC vs. placebo: N=82 OFC, N=335 placebo. bData from Calabrese et al, 2005, Am. J. Psychiatry, 
162 (7), 1351–1360; Thase et al, 2006, J. Clin. Psychopharmacol, 26 (6), 600–609. Number of patients, quetiapine vs. placebo: N=648 quetiapine benefit, N=330 placebo 
benefit, N=698 quetiapine harm, N=347 placebo harm. *p<0.001 vs. placebo. Adapted with permission from the Handbook of Diagnosis and Treatment of Bipolar Disorders, 
(Copyright © 2010). American Psychiatric Association. (Wang and Ketter, 2010). All rights reserved. MADRS = Montgomery–Åsberg Depression Rating Scale, NNH = number 
needed to harm, NNT = number needed to treat.
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Although antidepressants are very commonly administered 
for acute bipolar depression (Baldessarini et al., 2007), they 
generally (aside from fluoxetine combined with olanzapine) lack 
multicenter, randomized controlled trials demonstrating efficacy 
for bipolar depression or FDA indications for bipolar depression. 
The reasons underlying the common use of antidepressants in 
bipolar depression are likely complex, but may include their 
adequate efficacy in unipolar major depressive disorder; their 
adequate somatic tolerability, which is superior to that of MSs 
and SGAs (Figure 1); and the limited number of FDA-approved 
treatments for acute bipolar depression (Baldessarini et al., 
2007). However, substantial concerns have been raised that 
antidepressants in BD patients may be ineffective (Nemeroff et al., 
2001; Sachs et al., 2007) or may yield TEAS (Truman et al., 2007).
A recent meta-analysis of 6 double-blind, placebo-controlled 
studies of primarily adjunctive (added to antimanic agents) 
Fig 3. Benefits and harms of unapproved bipolar depression treatment: olanzapine. Number needed to treat (response) and number needed to harm (adverse effect rates). 
Olanzapine was almost more likely to yield harm as benefit compared with placebo, with inadequate efficacy. aData from Tohen et al, 2003, Arch. Gen. Psychiatry, 60 (11), 
1079–1088; Number of patients, OFC US trial: N=351 olanzapine benefit, N=355 placebo benefit, N=347 olanzapine harm, N=355 placebo harm. bData from Tohen et al, 2012, 
Br. J. Psychiatry, 201 (5), 376–382; Number of patients, International trial: N=343 olanzapine benefit, N=171 placebo benefit, N=341 olanzapine harm, N=169 placebo harm. 
*p<0.05 vs. placebo. †p<0.001 vs. placebo. Adapted with permission from the Handbook of Diagnosis and Treatment of Bipolar Disorders, (Copyright © 2010). American 
Psychiatric Association. (Wang and Ketter, 2010). All rights reserved. MADRS = Montgomery–Åsberg Depression Rating Scale, NNH = number needed to harm, NNT = 
number needed to treat, OFC = olanzapine-fluoxetine combination.
Fig 4. Benefits and harms of older unapproved bipolar depression treatments: lamotrigine and antidepressants. Number needed to treat (response/remission) and number 
needed to harm (adverse effect rates). Lamotrigine and antidepressants were unlikely to yield harm compared with placebo, but at the cost of inadequate efficacy. aData 
from Calabrese et al, 2008, Bipolar Disord., 10 (2), 323–333; Geddes et al, 2009, Br. J. Psychiatry, 194 (1), 4–9; Number of patients, lamotrigine vs. placebo: N=541 lamotrigine 
benefit, N=530 placebo benefit, N=402 lamotrigine harm, N=397 placebo harm. bData from Sidor and MacQueen, 2011, J. Clin. Psychiatry, 72 (2), 156–167; Number of patients, 
antidepressants vs. placebo: N=410 antidepressants benefit, N=608 placebo benefit, N=416 antidepressants harm, N=610 placebo harm. *p<0.01 vs. placebo. †Antidepressants 
used in the studies included in the meta-analysis were paroxetine, fluoxetine, imipramine, and bupropion. ‡One antidepressant study in this analysis assessed remission 
instead of response. Adapted with permission from the Handbook of Diagnosis and Treatment of Bipolar Disorders, (Copyright © 2010). American Psychiatric Association. 
(Wang and Ketter, 2010). All rights reserved. MADRS = Montgomery–Åsberg Depression Rating Scale, NNH = number needed to harm, NNT = number needed to treat.
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antidepressants in acute bipolar depression (with approximately 
90% of patients having bipolar I disorder) included 416 patients 
taking antidepressants and 610 taking placebo (Sidor and 
MacQueen, 2011). However, 1 study (the olanzapine plus 
fluoxetine registration study) accounted for approximately 42% 
of these patients (Tohen et al., 2003) and another contributed 
approximately 32% of the patients (Sachs et al., 2007), so that 
the remaining 4 studies accounted for only approximately 26% 
of all patients (Amsterdam and Shults, 2005; Cohn et al., 1989; 
Nemeroff et al., 2001; Shelton and Stahl, 2004). In this meta-
analysis, antidepressants had a favorable triple-digit NNH for 
TEAS of 200 (95% CI was NS); however, this was in the context 
of an unfavorable double-digit NNT of 29 (95% CI was also NS) 
(Figure 4, right) (Sidor and MacQueen, 2011). Thus, although 
antidepressants were numerically more likely to yield benefit 
(response) than harm (mood switch) compared with placebo, the 
favorable benefit/harm ratio was offset by inadequate efficacy. Not 
included in this meta-analysis was a recent multicenter, double-
blind, placebo-controlled study in which paroxetine monotherapy 
(N=118) compared with placebo (N=121) similarly yielded a 
favorable double-digit NNH for TEAS of 56 (95% CI was NS), albeit 
in the context of an unfavorable double-digit NNT of 46 (95% CI 
was also NS; not illustrated) (McElroy et al., 2010).
Thus, lamotrigine and antidepressants, compared with the 2 
older FDA-approved treatments for acute bipolar depression, both 
appeared to yield enhanced (adequate) tolerability at the cost of 
poorer (inadequate) efficacy.
6. Newer approved and emerging treatments for bipolar 
depression
In 2013, lurasidone received FDA approval for acute major 
depressive episodes in patients with bipolar I disorder (i.e., 
acute bipolar I depression), not only as monotherapy, but also 
as adjunctive therapy (added to lithium or valproate), based 
on adequately sized, multicenter, randomized, double-blind, 
placebo-controlled trials that demonstrated efficacy in acute 
bipolar depression in patients with bipolar I disorder (Loebel et 
al., 2014a; Loebel et al., 2014b).
Among adults with acute bipolar I depression, lurasidone 
monotherapy compared with placebo had an NNT for response 
of 5 (4–8) and an NNH for akathisia of 15 (10–33) (Figure 5, left) 
(Citrome et al., 2014; Loebel et al., 2014a). Therefore, lurasidone 
monotherapy compared with placebo was not only efficacious, but 
was more likely to yield benefit (response) than harm (akathisia). 
Additionally, lurasidone adjunctive therapy (added to lithium or 
valproate) compared with placebo had an NNT for response of 7 
(4–24) and an NNH for nausea of 16 (95% CI was NS) (Figure 5, 
right) (Citrome et al., 2014; Loebel et al., 2014b). Thus, lurasidone 
adjunctive therapy compared with placebo was numerically (the 
95% CIs for nausea was NS) more likely to yield benefit (response) 
than harm (nausea). Hence, lurasidone, whether administered as 
monotherapy or adjunctive therapy, appeared to have a favorable 
benefit/harm ratio that was not offset by reduction in efficacy, 
making lurasidone an important new treatment option for bipolar 
I depression.
Variable results have been presented for the low-affinity 
dopamine transporter inhibitor armodafinil. One adequately sized, 
multicenter, randomized, double-blind, placebo-controlled trial of 
adjunctive armodafinil therapy (added to FDA-approved bipolar 
maintenance treatments other than quetiapine) demonstrated 
efficacy for acute depression in patients with bipolar I disorder 
(Calabrese et al, 2014). However, a second such trial was negative 
(Frye et al., 2013), as was a third such trial (Adler et al., 2014; Frye 
et al., 2014).
In the first trial, in adults with acute bipolar I depression, 
adjunctive armodafinil therapy (added to lithium, valproate, 
olanzapine, risperidone, aripiprazole, or MS plus ziprasidone) 
compared with placebo had an NNT for response of 9 (5–43) and 
an NNH for anxiety of 29 (17–107) (Figure 6, left) (Calabrese et 
al., 2014). Thus, armodafinil adjunctive therapy compared with 
placebo was not only efficacious, but was numerically (the 95% 
CIs overlapped) more likely to yield benefit (response) than 
harm (anxiety). However, in the second and third acute bipolar 
Fig 5. Benefits and harms of newer approved bipolar depression treatment: lurasidone. Number needed to treat (response) and number needed to harm (adverse effect 
rates). Lurasidone monotherapy was more likely to yield benefit than harm, compared with placebo, with adequate efficacy. Lurasidone adjunctive therapy was numerically 
more likely to yield benefit than harm compared with placebo. The mean modal daily dose of lurasidone, low- and high-dose groups combined, was 62.7 mg/day in 
the monotherapy study and 66.3 mg/day in the adjunctive study. aData from Loebel et al, 2014a, Am. J. Psychiatry, 171 (2), 160–168; Number of patients, lurasidone 
monotherapy vs. placebo: N=323 lurasidone benefit, N=162 placebo benefit, N=331 lurasidone harm, N=168 placebo harm. bData from Loebel et al, 2014b, Am. J. Psychiatry, 
171 (2), 169–177; Number of patients, adjunctive lurasidone vs. placebo: N=179 lurasidone benefit, N=161 placebo benefit, N=183 lurasidone harm, N=163 placebo harm. 
*p<0.001 vs. placebo. †p<0.01 vs. placebo. MADRS = Montgomery–Åsberg Depression Rating Scale, NNH = number needed to harm, NNT = number needed to treat.
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depression trials, adjunctive armodafinil compared with placebo 
did not demonstrate efficacy, although tolerability was adequate 
(Adler et al., 2014; Frye et al., 2014; Frye et al., 2013).
7. Limitations
NNT and NNH are categorical (rather than continuous) 
metrics. The use of NNH for risk assessment may be limited for 
rare, serious, and more chronic side effects. Also, selection of 
the specific side effect of greatest interest varies across patients, 
limiting the applicability of NNHs used in this study for individual 
patients. Use of efficacy (versus effectiveness) studies entails less 
generalizability.
8. Conclusion
Analysis of NNT and NNH data show that lamotrigine 
and antidepressants yield better tolerability, compared with 
the two older FDA-approved treatments for acute bipolar 
depression (olanzapine-fluoxetine combination and quetiapine 
monotherapy), but at the cost of inadequate efficacy (Table 2). In 
contrast, more recent data indicate that lurasidone as monotherapy 
and as adjunctive therapy had better tolerability compared with 
the two older FDA-approved bipolar depression treatments, 
without compromising efficacy. Therefore, lurasidone appears to 
be an important new treatment option for bipolar I depression. 
Finally, although adjunctive armodafinil has yielded better 
Fig 6. Benefits and harms of investigational bipolar depression treatment: adjunctive armodafinil. Number needed to treat (response) and number needed to harm (adverse 
effect rates). In the first (but not second or third) trial, armodafinil was superior to placebo and numerically more likely to yield benefit than harm compared with placebo. 
Dose of armodafinil was 150 mg/d. aData from Calabrese et al, 2014, J. Clin. Psychiatry, published online ahead of print July 22, 2014; Number of patients, adjunctive 
armodafinil vs. placebo: N=197 armodafinil benefit, N=196 placebo benefit, N=198 armodafinil harm, N=199 placebo harm. *p<0.05 vs. placebo. IDS-C30 = 30 Item Inventory 
of Depressive Symptomatology–Clinician Rated, NNH = number needed to harm, NNT = number needed to treat.
Table 2
Benefits (NNTs) and harms (NNHs) of approved and unapproved bipolar depression treatments.
Reference Treatment NNT (95% CI) Side Effect NNH (95% CI) Benefit vs. Harm
 Approved     
Tohen et al., 2003 Olanzapine + fluoxetine  4 (3–8) ≥7% weight gain 6 (4–10) CIs overlap
Calabrese et al., 2005;  Quetiapine  6 (5–9) Sedation/somnolence 5 (4–5) CIs overlap 
Thase et al., 2006
Loebel et al., 2014a Lurasidone  5 (4–8) Akathisia 15 (10–33) Benefit>harm
Loebel et al., 2014b Lurasidone (adjunctive)  7 (4–24) Nausea 16 (NS) NC
 Unapproved     
Tohen et al., 2003 Olanzapine (olanzapine +  12 (7–63) ≥7% weight gain 6 (5–7) CIs overlap
 fluoxetine trial) 
Tohen et al., 2012 Olanzapine (international trial)  11 (6–1130) ≥7% weight gain 5 (4–6) CIs overlap
Calabrese et al., 2008;  Lamotrigine  12 (8–41) Sedation/somnolence 37 (NS) NC 
Geddes et al., 2009
Sidor and MacQueen, 2011 Antidepressants (adjunctive)  29 (NS) TEAS 200 (NS) NC
McElroy et al., 2010 Paroxetine  46 (NS) TEAS 56 (NS) NC
Calabrese et al., 2014 Armodafinil (adjunctive) 9 (5–43) Anxiety 29 (17–107) CIs overlap
CI = confidence interval; NC = not calculated (at least one 95% CI is NS); NNH = number needed to harm for specific side effect compared with placebo; NNT = 
number needed to treat for response compared with placebo; NS = non-significant (infinite/discontinuous) confidence interval; TEAS = treatment-emergent 
affective switch.
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tolerability compared with the two older FDA-approved bipolar 
depression treatments, its efficacy in bipolar I depression has not 
been consistently demonstrated.
Older FDA-approved bipolar depression treatments, such as the 
olanzapine-fluoxetine combination and quetiapine monotherapy, 
may still have utility in high-urgency situations, where a pressing 
clinical need for efficacy mitigates their tolerability shortcomings. 
In contrast, the older treatments lamotrigine and antidepressants, 
and possibly the newer treatment adjunctive armodafinil, none 
of which are approved for acute bipolar depression therapy, may 
have utility in low-urgency situations, in which a compelling 
need for tolerability might mitigate their efficacy shortcomings. 
Lurasidone may ultimately prove to have utility in a broad 
spectrum of situations, independent of the degree of urgency, 
because of evidence suggesting not only adequate efficacy, but 
also adequate tolerability.
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